series-a
Stage
1
Investors
About
Gennao Bio develops targeted nucleic acid therapeutics by using proprietary cell-penetrating monoclonal antibodies to deliver nucleic acid payloads specifically to selected cells, with a focus on oncology and rare skeletal muscle diseases.
Explore Gennao Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.